N/A N=10 V2 Receptor Effects on Fluid Regulation and Performance
Electrolyte Imbalance · Hyponatremia · Hypernatremia
Primary: Sweat Sodium Concentration Obtained After the Steady-state Portion of the Trial — 80.1; 76.8; 84.7 mEq/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 2 N=50 Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Leukemia · Lymphoma
Primary: Overall Response — 11; 23; 4; 5 participants
Phase 2 N=17 Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
Bladder Cancer
Primary: Arm A: Progression Free Survival (PFS) — 8 participants
Phase 3 N=56 Kuvan® in Phenylketonuria Patients Less Than 4 Years Old
Phenylketonuria
Primary: Dietary Phenylalanine (Phe) Tolerance at Week 26 — 80.6; 50.1 mg/kg/day
N/A N=24 Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
Acute Alcohol Withdrawal
Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64
N/A N=10 Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen
Open Abdomen
Primary: To Evaluate the Performance of the Dressing Kit as Part of a Negative Pressure System in Post Market Clinical Follow-up Settings — 4; 3; 2; 1 number of surgeons
Phase 2 N=45 Effect of Miswak and Miswak Extract on Oral Malodor
Oral Malodor · Halitosis
Primary: Organoleptic Scores After the First Use of the Prescribed Method by 15 Minutes (Masking Effect), and After 7 Days of Use (Therapeutic Effect). — 2.10; 1.62; 1.36; 1.10…
Phase 4 N=36 Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
Stable Coronary Heart Disease (CHD)
Primary: IPA on Day 1 — 27.09; 25.87; 33.34; 57.20 % IPA
Phase 2 N=164 Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
Prostate Cancer
Primary: Percentage of Participants Experiencing Neither of the 2 Mineralocorticoid Excess Toxicity During the First 24 Weeks of Treatment — 70.6; 36.8; 60.0; 70.3 Percentage of…
Phase 2 N=10 Oral Nadolol for the Treatment of Adults With Mild Asthma
Asthma
Primary: Mean Daily Dose at Study Termination Across Participants — 29.6 mg
N/A N=66 Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 26.4; 24.5; 28.8 percentage of total area
Phase 4 N=5,570 A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
Type 2 Diabetes Mellitus
Primary: Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2) — -0.65; -0.62; -0.46; -0.69 Percent
Phase 2 N=120 Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Metastatic Breast Cancer
Primary: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population…
N/A N=325 TOBY (TOtal Body hYpothermia): a Study of Treatment for Perinatal Asphyxia
Asphyxia Neonatorum · Hypoxia · Encephalopathy
Primary: Combined Incidence of Mortality and Severe Neurodevelopmental Disability in Survivors — 74; 86 participants